Averion International Corp. Announces Organizational Realignment

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Averion International Corp. (OTC BB: AVRO), a full- service international clinical research organization (CRO) specializing in oncology, cardiovascular diseases and medical devices, today appointed Peter Gonze as President and announced the appointment of James McGuire as Chairman of the Board of Directors. Dr. Markus Weissbach, who has been the CEO of Averion since the Hesperion acquisition in October 2007, moves to the position of Executive Chairman, reporting directly to Mr. McGuire, His responsibilities will include strategy and planning for Averion. Dr. Weissbach will also continue to provide support for key client activities, including the expansion of the cardiovascular practice. Dr. Philip Lavin, formerly Executive Chairman, also reports directly to Mr. McGuire with the title of Founder and Vice Chairman of the Board; he will continue to focus on client support inclusive of medical devices and regulatory interactions.